Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.42 |
| ▸ | ACACA | Q13085 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24631462 | 1.00 | ACACB (0.42) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631671 | 1.00 | ACACB (0.42) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631825 | 0.90 | ACACB (0.43) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30134736 | 0.90 | ACACB (0.43) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631455 | 0.90 | ACACB (0.43) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30134766 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30134764 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631674 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631670 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30031182 | 0.80 | ACACB (0.40) | ACACBACACADRD2CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4319738-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022217265-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TAAR1, TAAR5, NPY1R | ACACB 4730/4885ACACA 4533/4885DRD2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.